Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
COPA syndrome Indication Strategy Report 2026: STING, Trials and Deals
Latest Hotspot
8 min read
COPA syndrome Indication Strategy Report 2026: STING, Trials and Deals
30 July 2026
2026 COPA syndrome indication strategy covering epidemiology, STING biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Deficiency of adenosine deaminase 2 Indication Strategy Report 2026: ADA2, Trials and Deals
Latest Hotspot
8 min read
Deficiency of adenosine deaminase 2 Indication Strategy Report 2026: ADA2, Trials and Deals
30 July 2026
2026 Deficiency of adenosine deaminase 2 indication strategy covering epidemiology, ADA2 biology, active trials, transactions, unmet need, competition and market…
Read →
Blau syndrome Indication Strategy Report 2026: NOD2, Trials and Deals
Latest Hotspot
8 min read
Blau syndrome Indication Strategy Report 2026: NOD2, Trials and Deals
30 July 2026
2026 Blau syndrome indication strategy covering epidemiology, NOD2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Majeed syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Majeed syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Majeed syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Cherubism Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Cherubism Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Cherubism indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
PASH syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
PASH syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 PASH syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
TNF receptor-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
TNF receptor-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 TNF receptor-associated periodic syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Read →
PAPA syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
PAPA syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 PAPA syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Mevalonate kinase deficiency Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Mevalonate kinase deficiency Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Mevalonate kinase deficiency indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market…
Read →
Deficiency of interleukin-1 receptor antagonist Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Deficiency of interleukin-1 receptor antagonist Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Deficiency of interleukin-1 receptor antagonist indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need,…
Read →
Cryopyrin-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Cryopyrin-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Cryopyrin-associated periodic syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Read →
TAFRO syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
Latest Hotspot
8 min read
TAFRO syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
30 July 2026
2026 TAFRO syndrome indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →